One of Merck's pivotal stomach cancer trials for Keytruda flops, just months after an FDA OK
Less than three months after Merck $MRK won an accelerated OK to market Keytruda as a third-line drug for stomach cancer, the pharma giant says …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
